Molecular Mechanisms of Resistance to KRASG12C Inhibitors in NSCLC- From Genomic Evolution to TME Adaptation.
The clinical breakthrough achieved with KRASG12C inhibitors is limited in therapeutic response by the remarkable adaptive capacity of KRAS-mutant tumors. The drug resistance emerges through a dynamic interplay between tumor intrinsic and micro-environmental mechanisms. At the cellular level, there may be a rebound of K...